Products Affected - Description
Reserpine oral tablets, Sandoz
0.1 mg, 100 count (NDC 00185-0032-01)
0.1 mg, 1000 count (NDC 00185-0032-10)
0.25 mg, 100 count (NDC 00185-0134-01)
0.25 mg, 100 count (NDC 00185-0134-10)
Reason for the Shortage
- Sandoz said the shortage is due to a delay in obtaining raw materials.
- There are no other manufacturers of reserpine tablets.
No presentations are available.
Estimated Resupply Dates
Sandoz has all reserpine tablet presentations temporarily unavailable and the company cannot estimate a release date.
September 18, 2014; June 5, 2014; March 5, 2014; December 12, 2013; September 18, 2013; July 29, 2013; May 22, 2013; April 23, 2013; January 18, 2013; November 16, 2012, University of Utah, Drug Information Service. Copyright 2014, Drug Information Service, University of Utah, Salt Lake City, UT.
This information is provided through the support of Novation to ASHP solely as a service to its members, which shall not use this information for their further commercial use. The content was prepared by the Drug Information Center of University of Utah. Novation, ASHP, and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, which respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither Novation, ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this bulletin. Neither Novation, ASHP nor University of Utah endorses or recommends the use of any drug.
« Back to Drug Shortage Product Bulletins